Skip to Main Content

Practice Resources

ADHD resources for you and your patients

Click the heading to scroll to the section

Dosing calculators Dosing
calculators Savings cards Savings
Card ADHD resources Patient
resources ADHD community resources ADHD community
resources

Visit the Resource Center

Click below to access prescribing resources for you and your patients.

Discover Patient Support, Prior Authorization, Access & Savings, Formulary Support, and more!

Resource Center

Dosing Calculators

DYANAVEL XR Liquid amphetamine extended-release oral suspension 2.5 mg/mL Logo/mL Logo

Savings Card

Tris Savings Card

Eligible patients pay $25 per prescription*

 
9 out of 10 commercially covered patients pay $25 or less for DYANAVEL XR with the Tris Savings Card

Access Tris Savings Card

Or text TRIS to TRIS4U (874748) for Mobile Savings Card.†

Prescribe DYANAVEL XR Tablets with guaranteed availability
Dyanavel perigon logo

You Prescribe, We Deliver

ePrescribe DYANAVEL XR Tablets to Perigon Pharmacy 360 for guaranteed availability, patient support, free, fast delivery, and the lowest available price for your patients.

Learn more

Patient Resources

Tris ADHD DXRT Patient Brochure

DYANAVEL XR Tablet Patient Brochure

Download this guide for your patients so that they can learn more about ADHD, DYANAVEL XR, support, and resources.

Download in English

Download in Spanish

ADHD Community Resources

AAP/Healthy Children

AAP/Healthy Children

Healthy Children is the official American Academy of Pediatrics (AAP) website for parents, hosting a variety of articles that address common questions and issues in diagnosing and treating ADHD in children. Search for ADHD at healthychildren.org for information about topics like:

  • ADHD Myths and Misconceptions
  • ADHD Medications Daily Routines
  • Causes of ADHD: What We Know Today
ADDA

ADDA

The Attention Deficit Disorder Association (ADDA) is the world's leading adult ADHD association, dedicated to helping adults with ADHD lead better lives. Visit add.org to learn more about:

  • Adult ADHD Self-Screening Questionnaire
  • Virtual Peer Support Groups
  • Educational Resources
ADDitude Magazine

ADDitude Magazine

Online magazine for caregivers of children with attention deficit disorders. Visit additudemag.com to learn more.

CHADD

CHADD

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) is a nationally recognized nonprofit organization providing education, advocacy, and support for individuals with ADHD. Visit chadd.org

CDC

CDC

The Centers for Disease Control and Prevention (CDC) has published facts, research, statistics, and a wide array of other tools for parents to educate themselves about ADHD. Visit cdc.gov/ncbddd/adhd to learn more.

NIMH

NIMH

The National Institute of Mental Health (NIMH), a component of the US Department of Health and Human Services, provides in-depth information and resources on ADHD diagnosis and treatment at nimh.nih.gov.

Request more information about DYANAVEL XR

Click below to sign up to receive more infomation about DYANAVEL XR or request a visit from a Tris Pharma representative.

ADHD, Attention Deficit Hyperactivity Disorder.

IMPORTANT SAFETY INFORMATION

isi open close button

WARNING: ABUSE, MISUSE, AND ADDICTION

DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

IMPORTANT SAFETY INFORMATION

INDICATION

DYANAVEL® XR (amphetamine) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of use

The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

WARNING: ABUSE, MISUSE, AND ADDICTION

DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

  • DYANAVEL XR is contraindicated:
    • in patients known to be hypersensitive to amphetamine, or other components of DYANAVEL XR. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported with other amphetamines.
    • in patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of increased risk of hypertensive crisis.
  • Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD doses. Serious cardiovascular effects with overdose may precipitate sudden cardiac death. Prior to treating patients with DYANAVEL XR, assess for the presence of cardiac disease. Avoid DYANAVEL XR use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during DYANAVEL XR treatment.
  • CNS stimulants cause increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.
  • Use of CNS stimulants may cause exacerbation of pre-existing psychosis and may induce a manic or mixed episode in patients with bipolar disorder. In patients without prior history of psychotic illness or mania, CNS stimulants may cause new psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) at the recommended dosage. Prior to initiating DYANAVEL XR treatment, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing DYANAVEL XR.
  • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. DYANAVEL XR is not approved for use and is not recommended in pediatric patients below 6 years of age. Closely monitor height and weight in DYANAVEL XR treated pediatric patients treated with CNS stimulants. Treatment may need to be interrupted in children not growing or gaining height or weight as expected.
  • CNS stimulants, including DYANAVEL XR, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for DYANAVEL XR-treated patients who develop signs or symptoms of peripheral vasculopathy.
  • Serotonin syndrome risk is increased when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue DYANAVEL XR and any concomitant serotonergic agents immediately, and initiate supportive treatment.
  • CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Before initiating DYANAVEL XR, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor DYANAVEL XR-treated patients for the emergence or worsening of tics or Tourette’s syndrome and discontinue treatment if clinically appropriate.
  • Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia. Based on limited experience with DYANAVEL XR in controlled trials, the adverse reaction profile of DYANAVEL XR appears similar to other amphetamine extended-release products. The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (DYANAVEL XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
  • DYANAVEL XR use during pregnancy may cause fetal harm. To monitor pregnancy outcomes in women exposed to DYANAVEL XR during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
  • Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with DYANAVEL XR.
  • To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information for DYANAVEL XR including BOXED WARNING regarding ABUSE, MISUSE, and ADDICTION.

You are now leaving this website

You are about to leave DYANAVELXRhcp.com and enter a website operated by a third party. Would like to continue?

Yes